Description
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
This trial is available at multiple Sutter Locations. Please contact one of the following about Study SWOG S1706
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Isabel Rodrigues-Fong Rodrigi@sutterhealth.org and Kirsten Babski babskik@sutterhealth.org
Modesto: Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org and Mohammad Naseem NaseemMK@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
July 12, 2019
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.